



Press Kit

November 23rd, 2019

Here is some background information on JMCC:

<u>Company Profile</u>	4
--	---

<u>News Release: Top Global Cannabis Researchers to Gather in London for Medical Cannabis Research Symposium</u>	6
--	---

The Centre for Medicinal Cannabis (CMC) in partnership with the Jamaican Medical Cannabis Corporation (JMCC) announce their Global Medical Cannabis Research Symposium, which took place in London on 18-19 September 2019. This event showcased the latest developments in medicinal cannabis research.

<u>News Release: JMCC Becomes Exclusive Medical Supplier for Ground-breaking AML Treatment</u>	9
--	---

The Jamaican Medical Cannabis Corporation (JMCC) and Medicanga Limited, signed an agreement that JMCC will provide the high-quality medical cannabis required for clinical trials of a treatment for Acute Myeloid Leukemia (AML), which has won orphan drug designation by the United States Food and Drug Administration.



Company Profile

The Jamaican Medical Cannabis Corporation Group of Companies (JMCC) is a rapidly expanding enterprise with offices in Montego Bay and cultivation sites in various parishes including St. James and Hanover.

Recognizing the reputation of Jamaican farmers who have been growing an exceptional product for generations, and the island's ideal conditions for growing cannabis sustainably, JMCC chose Jamaica as the centre of its operations to produce high-quality medical marijuana for export globally – to countries including Canada, Australia, Germany and other countries that have legalized cannabis for medical and scientific purposes.

JMCC also offers an integrated and customizable outsourcing solution for the global medical cannabis industry, including processing/extraction, testing, global warehousing and distribution.

Senior members of the JMCC team include our Chief Agronomist (one of the most highly respected professionals in the country) as well as laboratory managers, processing and quality professionals, greenhouse technicians and more, supported by an international group of executives from highly regulated industries.

The company expects to employ approximately 150 Jamaicans by mid-2020 and is committed to becoming an “employer of choice” by providing competitive compensation, group health and pension benefits, and extensive training and development opportunities.

JMCC takes pride in our stringent, comprehensive quality management and other processes to ensure that the reputation of Jamaica medicinal cannabis is preserved and promoted worldwide.

JMCC's Commitment to Jamaica

JMCC believes that the engagement of small farmers, the development of local communities, and the advancement of research and education are critical to the success of the Jamaican cannabis industry. Our operations incorporate all of these elements as the company expands and becomes one of global significance.



Our commitments to Jamaica include:

- **Creating Employment:** JMCC is committed to providing well-compensated jobs, entrepreneurial and international business skills, and social development capacity in Jamaica by helping to develop a prosperous, sustainable medical cannabis industry. Employment opportunities are being created in a range of areas, including cultivation, quality management, analytical testing, processing, extraction, packaging, warehousing and logistics operations;
- **Corporate Social Responsibility:** We are committed to the communities in which we operate and have also established the JMCC foundation, 10², in which 10% of net profits over 10 years will be invested in an endowment to support local scientific, educational, environmental and community support programs;
- **Supporting Medical Research:** JMCC is the exclusive provider of the medical cannabis for the Phase 3 clinical trials for a treatment for Acute Myeloid Leukemia (AML), which was granted Orphan Drug Status by the U.S. Food and Drug Administration and developed by Dr. Henry Lowe. JMCC is providing the final product required by Dr. Lowe pro bono through its foundation, 10².

For more information, visit: <https://www.jamaicanmedicann.com>.

JMCC Spokespersons:

Diane Scott – Group Chief Executive Officer

Ashley-Ann Foster – General Counsel/Jamaican Director

Shelley Boyes – Global Director, Marketing and Communications

JMCC Jamaican Media Contact:

Andre Jebbinson – Communications Consultant

1-876-337-7341

E: andrejebbinson@hotmail.com

**Top Global Cannabis Researchers to Gather in London for Medical
Cannabis Research Symposium**



31 July 2019/London – Today, the Centre for Medicinal Cannabis (CMC) in partnership with the Jamaican Medical Cannabis Corporation (JMCC) announce their Global Medical Cannabis Research Symposium, which will take place in London on 18-19 September 2019.

This event, which will showcase the latest developments in medicinal cannabis research, could not be timelier given the imminent releases of NHS England and NICE reviews that are expected to call for the need for more evidence to support the prescribing of medicinal cannabis via the NHS. These calls are a response to the Secretary of State Matt Hancock expressing his ‘immense frustration’ at the lack of prescriptions of medical cannabis.

The two-day Global Medical Cannabis Research Symposium will bring together medical researchers and clinicians working on cannabis-based treatments from around the globe to share their research methodologies and findings with their UK peers. These include: medical cannabis pioneer Dr. Henry Lowe, who will discuss his cannabis-based FDA-approved “orphan drug” for Acute Myeloid Leukemia; leading Pediatric Epilepsy researcher and neurologist Dr Evan Lewis, and Dr. Regina Nelson, who specializes in male and female sexual health.

Other speakers include: The Hon. Professor Errol Morrison, Director General, Jamaican National Commission of Science and Technology; Dr. Saoirse O’Sullivan, Science Lead, Centre for Medicinal Cannabis; Greer Deal, Director, Global Regulatory Services; and Dr. David Horn, Medical Lead, Centre for Medicinal Cannabis.

Attendees will learn about current UK and international research projects focused on cancer, pediatric epilepsy, AML, gastrointestinal disorders, sexual dysfunction and other conditions. Panels and discussions will facilitate the exchange of experiences on research and clinical trial best practices and funding sources.

A multinational panel of patients will share their first-hand treatment experiences with delegates. The patient's voice will be represented by: Jeff Sawyer, Canada (Cancer Survivor); Gerald Major, Canada (Ankylosing



Spondylitis and Psoriatic Arthritis); Carly Barton, United Kingdom (Fibromyalgia) and Lina Eliasson, United Kingdom (Breast Cancer Survivor).

Attendees will also be brought up to speed on the latest UK medical cannabis law and policy developments and what they mean for medical research.

“The lack of evidence-based knowledge surrounding cannabis-based medicinal products is one of the key blocking factors as to why doctors in the UK are not prescribing despite recent law changes, said Steve Moore, CMC Founder and Director. “The Medical Cannabis Research Symposium will bring together some of the world’s leading experts on medicinal cannabis to share their findings and experiences with their UK peers. The goal is to encourage more UK-based research to not only provide the much-needed data but also to position the UK as a world leader in this field.”

“We’ve been fortunate in our travels to hear quite a bit about the many exciting medical cannabis research projects now in progress around the world, a few of which JMCC is supporting in different ways, said Diane Scott, Chair and CEO of the Jamaican Medical Cannabis Corporation Group of Companies. “So, we’re very pleased to help bring the researchers involved in a sample of these projects to London to discuss their work with members of the UK medical research community.

“At JMCC, our primary focus is on patients – delivering the safest, high-quality medical- grade cannabis available to researchers and medical product developers globally, she continued. “And we are absolutely aligned with the need for more research of all kinds into determining the real medical benefits cannabis may offer. After nearly 100 years – and counting -- of research-inhibiting prohibition, there is lots of catching up to do.”

--- END ---

About the Centre for Medicinal Cannabis

The Centre for Medicinal Cannabis (CMC) is the UK’s first and only industry



membership body for stakeholders operating in Cannabis Based Medicinal Products (CBMPs) and cannabidiol (CBD) wellness markets. We have a unique capability to engage intelligently and strategically with all influential political and public policy stakeholders, as well as relevant regulatory bodies, drawing on the experience from our global membership base. More information about The CMC can be found at www.thecmcuk.org.

About the Jamaican Medical Cannabis Corporation (JMCC)

JMCC is the premier provider of Jamaican medical cannabis to the world. We combine the country's natural, year-round growing climate and distinctive cannabis cultivars with an unswerving commitment to international quality standards to deliver superior products via state-of-the-science cultivation, quality assurance, testing, processing, packaging, warehousing and global distribution. The JMCC Foundation, 10², in which 10% of annual net profits will be invested over 10 years, is an endowment to support local scientific, educational, environmental and community support programs.

Learn more at <https://www.jamaicanmedicann.com/>

Contact:

Shelley Boyes

Global Director, Marketing & Communications JMCC

E: shelley.boyes@jamaicanmedicann.com

T: +1 416 272 8981



JMCC Becomes Exclusive Medical Supplier for Ground-breaking AML Treatment

May 15, 2018/Kingston – Under an agreement signed today by the Jamaican Medical Cannabis Corporation (JMCC) and Medicanga Limited, JMCC will provide the high-quality medical cannabis required for clinical trials of a treatment for Acute Myeloid Leukemia (AML), which has won orphan drug designation by the United States Food and Drug Administration.

JMCC will provide the dried cannabis on a pro-bono basis through its charitable foundation, 10², in which JMCC is investing 10% of its annual net profits over 10 years as an endowment to support local scientific, educational, environmental and community support programs.

Dr. Henry Lowe, founder and chair of Medicanga, said that JMCC's contribution was particularly welcome as the medical cannabis to be provided would be cultivated and processed in Jamaica, enabling the island to showcase the quality of its medical product.

"Not only is Jamaica home to Medicanga, it is entirely appropriate that we use Jamaica's own sustainably sun-grown, premier ganja in the development of this important new AML treatment," he said. "We are gratified both by JMCC's support and its investment in Jamaica, its economy and people."

Chair & CEO of the JMCC Group of Companies Diane Scott said: "We are extremely proud to be working with Dr Lowe, who is a true pioneer in medical research involving cannabis-based treatments," she said. "And we look forward to a long association with him as he goes on to develop other medical innovations as gifts to mankind."

AML (also called Acute Myelogenous Leukemia) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cells. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated. Globally, AML typically affects about one million people and results in 150,000 annually deaths. It most commonly occurs in older adults with males affected more often than females. The usual treatment is aggressive chemotherapy.



The U.S. Orphan Drug Act (ODA) provides for granting special status to a drug or biological product to treat a rare disease or condition, often to encourage development of treatments that have only limited commercial scope because of the relative rarity of the diseases. This status is referred to as orphan designation or sometimes “orphan status”.

--- END ---

For more information, contact:

Shelley Boyes
Global Director, Marketing & Communications
JMCC
Tel: +1 416 272 8981
E: Shelley.Boyes@jamaicanmedicann.com

About the Jamaican Medical Cannabis Corporation Group of Companies (JMCC)

JMCC is the premier provider of Jamaican medical cannabis to the world. We combine the country’s natural, year-round growing climate and distinctive cannabis cultivars with an unswerving commitment to international quality standards to deliver superior products via state-of-the-science cultivation, quality assurance, testing, processing, packaging, warehousing and global distribution.

Learn more at <https://www.jamaicanmedicann.com/>

About Medicanja Limited

Medicanja Limited was established in December 2013 by Dr. Henry Lowe to chart the way forward in the development of a medical marijuana industry in Jamaica. The company’s vision is to become the regional hub for the commercialization of world-class medicinal and therapeutic cannabis products. MCJ envisages being a leader in the transfer of knowledge and stimulation of increased interest in cannabis science globally.

Prof. the Hon. Henry Lowe has contributed approximately 50 years in the fields of science, technology, and the health sciences nationally, regionally and internationally. His recognitions include the Prime Minister’s National Medal in Science & Technology, Order of Jamaica, and Commander of the Order of Distinction.

Learn more at <http://www.medicanjajamaica.com>